Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Acta Neurol Scand. 2017 Nov;136 Suppl 201:15-17. doi: 10.1111/ane.12845.
Although it is clear that the immune system is an important disease driver in multiple sclerosis (MS), it is presently unknown what initiates the process. Infections have been mentioned as potential triggers, which is specifically dealt with in other articles of this volume. Here, I give an overview of two fluid biomarkers that reflect key elements of the MS process: microglial activation (cerebrospinal fluid [CSF] sTREM2) and axonal injury (CSF and serum/plasma neurofilament light). I review recent data on how these markers are altered in MS, how they change in relation to disease progression and treatment and, finally, how they can be used as tools in MS research.
虽然很明显免疫系统是多发性硬化症（MS）的重要疾病驱动因素，但目前尚不清楚是什么引发了这一过程。感染已被提及为潜在的触发因素，这在本卷的其他文章中进行了专门讨论。在这里，我概述了反映 MS 过程关键要素的两种流体生物标志物：小胶质细胞激活（脑脊液[sTREM2]）和轴突损伤（脑脊液和血清/血浆神经丝轻链）。我回顾了最近关于这些标志物在 MS 中如何改变、它们与疾病进展和治疗的关系以及最终如何将它们用作 MS 研究工具的相关数据。
